Literature DB >> 20843788

Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity.

Shaoliang Li1, Chisei Shimono, Naoko Norioka, Itsuko Nakano, Tetsuo Okubo, Yoshiko Yagi, Maria Hayashi, Yuya Sato, Hitomi Fujisaki, Shunji Hattori, Nobuo Sugiura, Koji Kimata, Kiyotoshi Sekiguchi.   

Abstract

Activin A, a member of the transforming growth factor-β family, plays important roles in hormonal homeostasis and embryogenesis. In this study, we produced recombinant human activin A and examined its abilities to bind to extracellular matrix proteins. Recombinant activin A expressed in 293-F cells was purified as complexes of mature dimeric activin A with its pro-region. Among a panel of extracellular matrix proteins tested, recombinant activin A bound to perlecan and agrin, but not to laminins, nidogens, collagens I and IV, fibronectin, and nephronectin. The binding of recombinant activin A to perlecan was inhibited by heparin and high concentrations of NaCl and abolished by heparitinase treatment of perlecan, suggesting that activin A binds to the heparan sulfate chains of perlecan. In support of this possibility, recombinant activin A was capable of directly binding to heparin and heparan sulfate chains. Site-directed mutagenesis of recombinant activin A revealed that clusters of basic amino acid residues, Lys(259)-Lys(263) and Lys(270)-Lys(272), in the pro-region were required for binding to perlecan. Interestingly, deletion of the peptide segment Lys(259)-Gly(277) containing both basic amino acid clusters from the pro-region did not impair the activity of activin A to stimulate Smad-dependent gene expressions, although it completely ablated the perlecan-binding activity. The binding of activin A to basement membrane heparan sulfate proteoglycans through the basic residues in the pro-region was further confirmed by in situ activin A overlay assays using frozen tissue sections. Taken together, the present results indicate that activin A binds to heparan sulfate proteoglycans through its pro-region and thereby regulates its localization within tissues.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20843788      PMCID: PMC2978593          DOI: 10.1074/jbc.M110.177865

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

Review 1.  Growth factor binding to the pericellular matrix and its importance in tissue engineering.

Authors:  Lauren Macri; David Silverstein; Richard A F Clark
Journal:  Adv Drug Deliv Rev       Date:  2007-08-16       Impact factor: 15.470

2.  Transcriptome-based systematic identification of extracellular matrix proteins.

Authors:  Ri-ichiroh Manabe; Ko Tsutsui; Tomiko Yamada; Mina Kimura; Itsuko Nakano; Chisei Shimono; Noriko Sanzen; Yutaka Furutani; Tomohiko Fukuda; Yasuko Oguri; Keiko Shimamoto; Daiji Kiyozumi; Yuya Sato; Yoshikazu Sado; Haruki Senoo; Shohei Yamashina; Shiro Fukuda; Jun Kawai; Nobuo Sugiura; Koji Kimata; Yoshihide Hayashizaki; Kiyotoshi Sekiguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

Review 3.  Elucidation of the role of activin in organogenesis using a multiple organ induction system with amphibian and mouse undifferentiated cells in vitro.

Authors:  Makoto Asashima; Tatsuo Michiue; Akira Kurisaki
Journal:  Dev Growth Differ       Date:  2008-04-22       Impact factor: 2.053

4.  Monomeric activin A retains high receptor binding affinity but exhibits low biological activity.

Authors:  P Hüsken-Hindi; K Tsuchida; M Park; A Z Corrigan; J M Vaughan; W W Vale; W H Fischer
Journal:  J Biol Chem       Date:  1994-07-29       Impact factor: 5.157

5.  Regulation of bone morphogenetic protein-4 activity by sequence elements within the prodomain.

Authors:  Shailaja Sopory; Sylvia M Nelsen; Catherine Degnin; Crispin Wong; Jan L Christian
Journal:  J Biol Chem       Date:  2006-09-11       Impact factor: 5.157

6.  Endogenous heparan sulfate and heparin modulate bone morphogenetic protein-4 signaling and activity.

Authors:  Shaukat A Khan; Matthew S Nelson; Chendong Pan; Patrick M Gaffney; Pankaj Gupta
Journal:  Am J Physiol Cell Physiol       Date:  2008-04-02       Impact factor: 4.249

7.  Type IV collagens regulate BMP signalling in Drosophila.

Authors:  Xiaomeng Wang; Robin E Harris; Laura J Bayston; Hilary L Ashe
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

8.  A new model for growth factor activation: type II receptors compete with the prodomain for BMP-7.

Authors:  Gerhard Sengle; Robert N Ono; Karen M Lyons; Hans Peter Bächinger; Lynn Y Sakai
Journal:  J Mol Biol       Date:  2008-07-02       Impact factor: 5.469

9.  Targeting of bone morphogenetic protein growth factor complexes to fibrillin.

Authors:  Gerhard Sengle; Noe L Charbonneau; Robert N Ono; Takako Sasaki; Jennifer Alvarez; Douglas R Keene; Hans Peter Bächinger; Lynn Y Sakai
Journal:  J Biol Chem       Date:  2008-03-13       Impact factor: 5.157

Review 10.  Heparan sulphate proteoglycans fine-tune mammalian physiology.

Authors:  Joseph R Bishop; Manuela Schuksz; Jeffrey D Esko
Journal:  Nature       Date:  2007-04-26       Impact factor: 49.962

View more
  26 in total

Review 1.  Structural Biology and Evolution of the TGF-β Family.

Authors:  Andrew P Hinck; Thomas D Mueller; Timothy A Springer
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

2.  Structure of bone morphogenetic protein 9 procomplex.

Authors:  Li-Zhi Mi; Christopher T Brown; Yijie Gao; Yuan Tian; Viet Q Le; Thomas Walz; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-06       Impact factor: 11.205

3.  Identification and characterization of a novel heparan sulfate-binding domain in Activin A longest variants and implications for function.

Authors:  Evan Yang; Christina Mundy; Eric F Rappaport; Maurizio Pacifici; Paul C Billings
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

Review 4.  Activins and Inhibins: Roles in Development, Physiology, and Disease.

Authors:  Maria Namwanje; Chester W Brown
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

Review 5.  Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders.

Authors:  Mary C Farach-Carson; Curtis R Warren; Daniel A Harrington; Daniel D Carson
Journal:  Matrix Biol       Date:  2013-08-31       Impact factor: 11.583

6.  Injectable perlecan domain 1-hyaluronan microgels potentiate the cartilage repair effect of BMP2 in a murine model of early osteoarthritis.

Authors:  Padma P Srinivasan; Sarah Y McCoy; Amit K Jha; Weidong Yang; Xinqiao Jia; Mary C Farach-Carson; Catherine B Kirn-Safran
Journal:  Biomed Mater       Date:  2012-03-29       Impact factor: 3.715

7.  Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.

Authors:  Atul Goyal; Nutan Pal; Matthew Concannon; Matthew Paul; Mike Doran; Chiara Poluzzi; Kiyotoshi Sekiguchi; John M Whitelock; Thomas Neill; Renato V Iozzo
Journal:  J Biol Chem       Date:  2011-05-19       Impact factor: 5.157

8.  Protection of the Prodomain α1-Helix Correlates with Latency in the Transforming Growth Factor-β Family.

Authors:  Viet Q Le; Roxana E Iacob; Bo Zhao; Yang Su; Yuan Tian; Cameron Toohey; John R Engen; Timothy A Springer
Journal:  J Mol Biol       Date:  2022-01-04       Impact factor: 5.469

9.  Pretreatment with Perlecan-Conjugated Laminin-E8 Fragment Enhances Maturation of Grafted Dopaminergic Progenitors in Parkinson's Disease Model.

Authors:  Hiromasa Adachi; Asuka Morizane; Sadaharu Torikoshi; Fabian Raudzus; Yukimasa Taniguchi; Susumu Miyamoto; Kiyotoshi Sekiguchi; Jun Takahashi
Journal:  Stem Cells Transl Med       Date:  2022-07-20       Impact factor: 7.655

10.  Microfluidic fabrication of bioactive microgels for rapid formation and enhanced differentiation of stem cell spheroids.

Authors:  Christian Siltanen; Maliheh Yaghoobi; Amranul Haque; Jungmok You; Jeremy Lowen; Masoud Soleimani; Alexander Revzin
Journal:  Acta Biomater       Date:  2016-01-13       Impact factor: 8.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.